AZEMX Performance — Alger Emerging Markets Fund, Class Z
Data updated: 2026-09-25
AZEMX returned +17.87% year to date and +32.06% over one year to Jul 2026. Annualised returns are +16.32% over 3 years and +9.44% over 5 years. The fund trailed its Emerging Markets Equity category average: $100 invested three years ago grew to $157, against $164 for the category, and to $132 over one year, against $134. Volatility over the past three years was 14.85% a year. In the 12 months to Jul 2026 the fund lost a net $407K, and assets reached $22.35M.
AZEMX Growth of $100
What $100 invested in Alger Emerging Markets Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Emerging Markets Equity category average over the same months.
| Period | AZEMX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $132 | $134 |
| 3 years (Aug 2023 – Jul 2026) | $157 | $164 |
| 5 years (Aug 2021 – Jul 2026) | $157 | $143 |
| Since data start (Aug 2019 – Jul 2026) | $158 | $188 |
AZEMX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +17.87% |
| 1 year | +32.06% |
| 3 years (annualised) | +16.32% |
| 5 years (annualised) | +9.44% |
AZEMX Annual Returns
Calendar-year total returns of Alger Emerging Markets Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +17.87% |
| 2025 | +26.01% |
| 2024 | +5.99% |
| 2023 | +0.15% |
| 2022 | −0.36% |
| 2021 | −0.01% |
| 2020 | +0.36% |
| 2019 (Aug–Dec) | +0.10% |
AZEMX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.7% | +3.2% | −10.6% | +13.5% | +7.7% | +4.4% | −7.8% | — | — | — | — | — |
| 2025 | +1.8% | −0.6% | −0.4% | +1.5% | +4.4% | +6.4% | −1.1% | +2.5% | +5.7% | +2.3% | −0.8% | +2.0% |
| 2024 | −1.2% | +4.8% | +1.0% | −0.7% | +1.0% | +3.7% | +0.2% | +1.0% | +3.4% | −3.6% | −2.3% | −1.3% |
| 2023 | +0.1% | −0.1% | 0.0% | 0.0% | 0.0% | +0.1% | +0.1% | 0.0% | −0.1% | 0.0% | +0.1% | 0.0% |
| 2022 | −0.1% | −0.1% | 0.0% | −0.1% | 0.0% | 0.0% | 0.0% | 0.0% | −0.1% | 0.0% | +0.1% | 0.0% |
| 2021 | 0.0% | 0.0% | −0.1% | 0.0% | 0.0% | +0.1% | 0.0% | 0.0% | −0.1% | 0.0% | 0.0% | 0.0% |
| 2020 | 0.0% | 0.0% | −0.2% | +0.1% | +0.1% | +0.1% | +0.1% | 0.0% | 0.0% | 0.0% | +0.1% | +0.1% |
| 2019 | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | +0.1% |
AZEMX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 14.85%
- 3-year Sharpe ratio: 0.80 (vs 4.5% risk-free rate)
- Best month: +13.50% (Apr 2026)
- Worst month: −10.62% (Mar 2026)
AZEMX Fund Flows
Monthly money in and out of Alger Emerging Markets Fund, from SEC Form N-PORT.
- 12-month net flow: −$407K
- 12-month gross sales (incl. reinvestments): $5.0M
- Sales ÷ redemptions: 0.92×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $239K | $372K | −$133K |
| Jun 2026 | $918K | $1.3M | −$358K |
| May 2026 | $716K | $362K | $354K |
| Apr 2026 | $768K | $254K | $514K |
| Mar 2026 | $424K | $788K | −$365K |
| Feb 2026 | $428K | $188K | $240K |
| Jan 2026 | $231K | $578K | −$348K |
| Dec 2025 | $304K | $320K | −$16K |
| Nov 2025 | $180K | $628K | −$448K |
| Oct 2025 | $363K | $138K | $224K |
| Sep 2025 | $100K | $163K | −$63K |
| Aug 2025 | $304K | $313K | −$9K |
AZEMX Assets Under Management
Net assets of Alger Emerging Markets Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $22.35M |
| 2026-04-30 | $21.69M |
| 2026-01-30 | $20.39M |
| 2025-10-31 | $19.41M |
| 2025-07-31 | $17.41M |
| 2025-04-30 | $16.07M |
| 2025-01-31 | $17.43M |
| 2024-10-31 | $18.85M |
| 2024-07-31 | $19.96M |
| 2024-04-30 | $20.06M |
| 2024-01-31 | $20.44M |
| 2023-10-31 | $19.44M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.